Bevacizumab: all 1,786 studies that test it

Page 1 of 18. Open to participants first (285), then studies with results posted, then the rest; newest registration first within each.

• First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingNCT07893340Phase 2
• PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerRecruitingNCT07884877Phase 2
• SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingNCT07882056Phase 2
• A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal CancerNot yet recruitingNCT07854964Not applicable
• Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07843303Phase 2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid TumorsNot yet recruitingNCT07833735Phase 1/2
• Bevacizumab in the Treatment of HHTRecruitingNCT07828015Phase 2
• Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07821606Phase 3
• Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingNCT07819604Phase 2
• mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal CancerNot yet recruitingNCT07817888Phase 2
• ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularNot yet recruitingNCT07813572Phase 3
• A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaRecruitingNCT07812090Phase 2
• An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid TumorsNot yet recruitingNCT07774611Phase 1/2
• Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular CarcinomaNot yet recruitingNCT07774247Phase 2
• Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingNCT07761286Phase 1/2
• Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)Not yet recruitingNCT07756840Phase 2
• South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)Not yet recruitingNCT07753616Phase 4
• A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingNCT07750041Phase 1/2
• FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRCNot yet recruitingNCT07729605Phase 3
• Intra-Arterial Bevacizumab as an Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural HematomaNot yet recruitingNCT07729098Phase 1
• Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 TrialRecruitingNCT07722754Phase 2
• IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRecruitingNCT07722494Phase 3
• Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)Not yet recruitingNCT07714317Phase 1/2
• A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaNot yet recruitingNCT07691762Phase 3
• Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System DiseaseNot yet recruitingNCT07681297Phase 1/2
• A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal CancerRecruitingNCT07676162Phase 3
• Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term ProgressionRecruitingNCT07670026Phase 2
• Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingNCT07663513Phase 2
• A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung CancerNot yet recruitingNCT07661173Phase 2
• A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.RecruitingNCT07653685Phase 1/2
• Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian CancerNot yet recruitingNCT07647653Phase 2
• Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal NeovascularizationRecruitingNCT07642960Not applicable
• Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.RecruitingNCT07638852Phase 2
• Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian CancerNot yet recruitingNCT07637851Phase 1/2
• Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)RecruitingNCT07627347Not applicable
• Sac-TMT Combined With Bevacizumab in TNBC With Brain MetastasesRecruitingNCT07623577Phase 2
• A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT07619235Phase 4
• Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF AgentsRecruitingNCT07567833Phase 4
• A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular CarcinomaRecruitingNCT07557251Phase 1
• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)RecruitingNCT07549412Phase 3
• SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RCRecruitingNCT07549399Phase 3
• Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 TrialNot yet recruitingNCT07543783Phase 2
• SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal CancerNot yet recruitingNCT07535632Phase 2
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerRecruitingNCT07527858Phase 2
• Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine CarcinomaRecruitingNCT07518602Phase 2
• Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07515625Phase 2
• Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal CancerRecruitingNCT07500298Phase 1
• JSKN033 Combination Therapy in Subjects With Advanced Cervical CancerNot yet recruitingNCT07497074Phase 2
• Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain MetastasesRecruitingNCT07481786Phase 3
• A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT07478302Phase 1
• SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruitingNCT07472647Phase 1/2
• PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal CancerRecruitingNCT07472140Phase 2/3
• Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingNCT07446452Phase 2
• Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNot yet recruitingNCT07420439Phase 2
• Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.RecruitingNCT07407465Phase 2
• Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard TherapyRecruitingNCT07397819Phase 1/2
• LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS MutationNot yet recruitingNCT07391566Phase 1/2
• IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric CancerNot yet recruitingNCT07361991Phase 1/2
• Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBCEnrolling by invitationNCT07359404Phase 2
• MA-CRC-II-016 SHR-1811Not yet recruitingNCT07355764Phase 2
• Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual DiseaseRecruitingNCT07346157Phase 1/2
• A Multi-Arm, Platform Trial For Relapsed NeuroblastomaRecruitingNCT07334301Phase 1/2
• QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTTRecruitingNCT07327788Phase 2
• ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingNCT07288034Phase 2
• A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.RecruitingNCT07283367Phase 1/2
• Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07281664Not applicable
• Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and BevacizumabRecruitingNCT07276100Phase 2
• Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent GlioblastomaNot yet recruitingNCT07274787Not applicable
• Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialRecruitingNCT07263438Phase 2
• Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07244926Phase 2
• A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRCRecruitingNCT07244705Phase 1/2
• A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerRecruitingNCT07241767Phase 2
• Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoRecruitingNCT07239245Phase 2
• A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E MutationNot yet recruitingNCT07229846Phase 2
• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingNCT07213804Phase 3
• The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal CancerRecruitingNCT07204574Phase 1/2
• Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingNCT07198074Phase 3
• Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingNCT07193862Early Phase 1
• Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & BevacizumabRecruitingNCT07192185Phase 2
• High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLCNot yet recruitingNCT07182708Phase 2
• Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal CancerRecruitingNCT07150247Phase 2
• T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain MetastasisRecruitingNCT07150208Phase 2
• Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)Not yet recruitingNCT07134101Phase 2
• A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)Not yet recruitingNCT07128251Phase 2
• A Study of IBI363 Combination Therapy in Participants With Advanced Solid TumorsNot yet recruitingNCT07124793Phase 2
• Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein MarkerNot yet recruitingNCT07120451Phase 2
• Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian CancerNot yet recruitingNCT07117877Phase 2
• Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver MetastasesRecruitingNCT07117435Phase 1
• Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRCNot yet recruitingNCT07116577Phase 2
• Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II TrialRecruitingNCT07106034Phase 2
• Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)Not yet recruitingNCT07089719Phase 2
• A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST TrialRecruitingNCT07074756Not applicable
• BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC PatientsNot yet recruitingNCT07071844Phase 2
• Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRCNot yet recruitingNCT07070713Phase 2
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Phase 1
• RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingNCT07065435Phase 2
• BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or OligometastasesRecruitingNCT07062055Phase 2
• An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal CancerNot yet recruitingNCT07061210Phase 2
• Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal CancerNot yet recruitingNCT07059949Phase 2

← Bevacizumab overview